WO2005105066A8 - Histone deacetylases inhibitors against hyperlipidaemias, atherosclerosis, cardiovascular diseases - Google Patents
Histone deacetylases inhibitors against hyperlipidaemias, atherosclerosis, cardiovascular diseasesInfo
- Publication number
- WO2005105066A8 WO2005105066A8 PCT/IT2005/000248 IT2005000248W WO2005105066A8 WO 2005105066 A8 WO2005105066 A8 WO 2005105066A8 IT 2005000248 W IT2005000248 W IT 2005000248W WO 2005105066 A8 WO2005105066 A8 WO 2005105066A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- atherosclerosis
- histone deacetylases
- hyperlipidaemias
- cardiovascular diseases
- inhibitors against
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05742909A EP1746982A2 (en) | 2004-04-30 | 2005-04-29 | Histone deacetylases inhibitors against hyperlipidaemias, atherosclerosis and cardiovascular diseases |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITMI2004A000876 | 2004-04-30 | ||
IT000876A ITMI20040876A1 (en) | 2004-04-30 | 2004-04-30 | DEHACETYLASE-HDAC HISTONE INHIBITORS-WHICH HYPOLIPIDEMIZED AGENTS FOR THE THERAPY AND PREVENTION OF ARTERIOSCLEROSIS AND CARDIOVASCULAR DISEASES |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2005105066A2 WO2005105066A2 (en) | 2005-11-10 |
WO2005105066A8 true WO2005105066A8 (en) | 2006-04-13 |
WO2005105066A3 WO2005105066A3 (en) | 2006-05-18 |
Family
ID=34979580
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IT2005/000248 WO2005105066A2 (en) | 2004-04-30 | 2005-04-29 | Histone deacetylases inhibitors against hyperlipidaemias, atherosclerosis, cardiovascular diseases |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1746982A2 (en) |
IT (1) | ITMI20040876A1 (en) |
WO (1) | WO2005105066A2 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8691534B2 (en) | 2006-12-29 | 2014-04-08 | Celgene Corporation | Preparation of romidepsin |
US8859502B2 (en) | 2010-09-13 | 2014-10-14 | Celgene Corporation | Therapy for MLL-rearranged leukemia |
US8957027B2 (en) | 2006-06-08 | 2015-02-17 | Celgene Corporation | Deacetylase inhibitor therapy |
US8980825B2 (en) | 2010-07-12 | 2015-03-17 | Celgene Corporation | Romidepsin solid forms and uses thereof |
US9101579B2 (en) | 2012-11-14 | 2015-08-11 | Celgene Corporation | Inhibition of drug resistant cancer cells |
US9134325B2 (en) | 2012-09-07 | 2015-09-15 | Celgene Corporation | Resistance biomarkers for HDAC inhibitors |
US9463215B2 (en) | 2013-12-27 | 2016-10-11 | Celgene Corporation | Romidepsin formulations and uses thereof |
US9539303B2 (en) | 2006-04-24 | 2017-01-10 | Celgene Corporation | Treatment of Ras-expressing tumors |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008090534A1 (en) * | 2007-01-26 | 2008-07-31 | Berand Limited | Methods and compositions for inhibition of excessive weight gain, reduction of inappropriate eating behaviours and inhibition of binge eating for the treatment of obesity |
KR100909867B1 (en) * | 2007-04-16 | 2009-07-29 | 주식회사바이오러넥스 | Compositions for the Prevention and Treatment of Osteo Metabolic Diseases |
US20140314788A1 (en) * | 2010-04-09 | 2014-10-23 | Salk Institute For Biological Studies | Modulation of histone deacetylases for the treatment of metabolic disease, methods and compositions related thereto |
EP2389932A1 (en) * | 2010-05-28 | 2011-11-30 | Lunamed AG | Compositions for use in genetic disorders comprising 4-phenyl-butyric acid and its salts |
US20140051716A1 (en) * | 2011-03-09 | 2014-02-20 | Cereno Scientific Ab | Compounds and methods for improving impaired endogenous fibrinolysis using histone deacetylase inhibitors |
EP2599481A1 (en) * | 2011-11-30 | 2013-06-05 | Lunamed AG | 4-phenylbutyric acid for the treatment or prevention of various diseases |
MX2014007969A (en) * | 2011-12-29 | 2015-02-10 | Pharmacyclics Inc | Cinnamic acid hydroxyamides as inhibitors of histone deacetylase 8. |
GB201417828D0 (en) | 2014-10-08 | 2014-11-19 | Cereno Scient Ab | New methods and compositions |
JP6985368B2 (en) | 2016-04-08 | 2021-12-22 | セレノ・サイエンティフィック・アーベー | Delayed release pharmaceutical preparation containing valproic acid and its use |
PE20220711A1 (en) | 2019-09-27 | 2022-05-04 | Takeda Pharmaceuticals Co | DERIVATIVES OF 2-ISOINDOL-1,3,4-OXADIAZOLE USEFUL AS INHIBITORS OF HISTONE DEACETYLASE 6 (HDAC6) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6025369A (en) * | 1996-05-03 | 2000-02-15 | The Board Of Regents Of The University Nebraska | N-methyl-D-aspartate (NMDA) receptor blockers for the prevention of atherosclerosis |
EP1185259A1 (en) * | 1999-04-29 | 2002-03-13 | MERCK PATENT GmbH | Glycine cleavage system inhibitors as potential antipsychotics |
US6987131B1 (en) * | 2000-06-26 | 2006-01-17 | Burzynski Stanislaw R | Phenylacetic acid compositions for treating or preventing hypercholesterolemia |
US6191117B1 (en) * | 2000-07-10 | 2001-02-20 | Walter E. Kozachuk | Methods of producing weight loss and treatment of obesity |
US6884421B2 (en) * | 2002-03-27 | 2005-04-26 | Council Of Scientific And Industrial Research | Pharmaceutical composition for diabetic nephropathy |
-
2004
- 2004-04-30 IT IT000876A patent/ITMI20040876A1/en unknown
-
2005
- 2005-04-29 WO PCT/IT2005/000248 patent/WO2005105066A2/en active Application Filing
- 2005-04-29 EP EP05742909A patent/EP1746982A2/en not_active Withdrawn
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9539303B2 (en) | 2006-04-24 | 2017-01-10 | Celgene Corporation | Treatment of Ras-expressing tumors |
US8957027B2 (en) | 2006-06-08 | 2015-02-17 | Celgene Corporation | Deacetylase inhibitor therapy |
US9259452B2 (en) | 2006-06-08 | 2016-02-16 | Gelgene Corporation | Deacetylase inhibitor therapy |
US8691534B2 (en) | 2006-12-29 | 2014-04-08 | Celgene Corporation | Preparation of romidepsin |
US8980825B2 (en) | 2010-07-12 | 2015-03-17 | Celgene Corporation | Romidepsin solid forms and uses thereof |
US9518094B2 (en) | 2010-07-12 | 2016-12-13 | Celgene Corporation | Romidepsin solid forms and uses thereof |
US8859502B2 (en) | 2010-09-13 | 2014-10-14 | Celgene Corporation | Therapy for MLL-rearranged leukemia |
US9134325B2 (en) | 2012-09-07 | 2015-09-15 | Celgene Corporation | Resistance biomarkers for HDAC inhibitors |
US9101579B2 (en) | 2012-11-14 | 2015-08-11 | Celgene Corporation | Inhibition of drug resistant cancer cells |
US9463215B2 (en) | 2013-12-27 | 2016-10-11 | Celgene Corporation | Romidepsin formulations and uses thereof |
US9468664B2 (en) | 2013-12-27 | 2016-10-18 | Celgene Corporation | Romidepsin formulations and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
WO2005105066A2 (en) | 2005-11-10 |
ITMI20040876A1 (en) | 2004-07-30 |
EP1746982A2 (en) | 2007-01-31 |
WO2005105066A3 (en) | 2006-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005105066A8 (en) | Histone deacetylases inhibitors against hyperlipidaemias, atherosclerosis, cardiovascular diseases | |
WO2007084319A3 (en) | Diaryl piperidines as cb1 modulators | |
WO2007118185A3 (en) | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme | |
WO2006074244A3 (en) | Adamantyl derivatives as inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme | |
WO2007109354A3 (en) | Peptide-peptidase inhibitor conjugates and methods of using same | |
WO2007056771A3 (en) | Compounds for the treatment of metabolic disorders | |
WO2006074330A3 (en) | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme | |
WO2007100535A3 (en) | Oxyntomodulin derivatives | |
IL202269A0 (en) | Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes | |
WO2009042922A3 (en) | Peptide-peptidase inhibitor conjugates and methods of making and using same | |
WO2007095601A3 (en) | Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome | |
AU2007243282A8 (en) | Compositions and methods for the treatment of cardiovascular disease | |
WO2010081079A3 (en) | Composition and method for treatment of diabetes | |
WO2012006298A3 (en) | Formulation for co-therapy treatment of diabetes | |
EP2579876A4 (en) | Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes | |
HK1125831A1 (en) | Fat accumulation inhibitor for the treatment of metabolic syndrome | |
WO2010077339A3 (en) | β-ARRESTIN EFFECTORS AND COMPOSITIONS AND METHODS OF USE THEREOF | |
EP2646032A4 (en) | Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity or prediabetes | |
EP2011492A4 (en) | Gip secretion inhibitor | |
WO2011038014A3 (en) | Composition and method for treatment of diabetes | |
WO2010045306A3 (en) | Azine derivatives and methods of use thereof | |
EP2010164A4 (en) | S-nitrosothiols containing compositions and the use of such compositions for the treatment of fatty liver diseases, obesity and other diseases associated with the metabolic syndrome and the use of such compositions | |
EP2114374A4 (en) | Pharmaceutical compositions of entacapone | |
WO2009074498A8 (en) | Medical use of 3- (2, 2, 2-trimethylhydrazinixm) propionate orotate | |
ZA200902005B (en) | Lipoxin A4 analogs for the treatment and prevention of intestinal fibrosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
CFP | Corrected version of a pamphlet front page | ||
CR1 | Correction of entry in section i |
Free format text: IN PCT GAZETTE 45/2005 UNDER (72, 75) THE ADDRESS OF "MITRO, NICO" SHOULD READ "VIA SAN ROCCO, 12, I-20135 MILANO (IT)." |
|
NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005742909 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2005742909 Country of ref document: EP |